Welcome to our dedicated page for Bayer A G news (Ticker: BAYZF), a resource for investors and traders seeking the latest updates and insights on Bayer A G stock.
The BAYZF news page on Stock Titan aggregates recent announcements and press releases related to Bayer AG, a global life science company with core competencies in health care and nutrition. Investors and observers can use this feed to follow how Bayer communicates about its pharmaceutical pipeline, radiology developments, crop science launches and broader corporate strategy.
Recent Bayer news has highlighted updates on its Pharmaceuticals Division, including growth plans built around high-value products and a modality-rich pipeline in oncology, cardiology, neurology, immunology and women’s health. Releases describe pivotal approvals, regulatory milestones, and clinical data from programs in areas such as stroke prevention, heart failure, chronic kidney disease, prostate cancer, lung cancer and menopause-related vasomotor symptoms.
The news flow also covers Bayer’s activities in radiology and molecular imaging, such as clinical results for an investigational low-dose MRI contrast agent and the acquisition of investigational PET and SPECT tracers for diagnosing cardiac amyloidosis. In addition, company communications report collaborations in advanced modalities like cell and gene therapy and siRNA-based treatments, as well as progress in rare kidney diseases including Alport Syndrome.
Beyond human health, Bayer’s crop science releases describe new insecticides and seed treatments for crops such as canola and pulses, illustrating its role in agricultural inputs and food production. Together, these updates provide context on how Bayer pursues its stated mission of “Health for all, Hunger for none” across pharmaceuticals, diagnostics and agriculture. For anyone tracking BAYZF, this news page offers a centralized view of the company’s reported clinical milestones, product launches, partnerships and strategic initiatives over time.
Bayer (OTC:BAYRY) agreed to acquire two investigational molecular imaging tracers from Attralus: AT-01 (124-iodine evuzamitide) and AT-05 (PAR-peptide + technetium-99m). AT-01 is in Phase III and holds FDA Breakthrough Therapy plus Orphan Drug designations (U.S. and EU); AT-05 is in Phase I. The acquisition expands Bayer into diagnostic tracers for cardiac and systemic amyloidosis, a disease estimated to affect ~400,000 people globally, and complements Bayer’s radiology and cardiovascular portfolio. Financial terms were not disclosed. Attralus will refocus on its therapeutic programs including AT-02 in Phase II.
Bayer (OTC: BAYRY) and Soufflé Therapeutics announced a strategic collaboration and global license to develop a cell-selective, heart-targeted siRNA therapy for a form of dilated cardiomyopathy affecting a rare subset of patients. The partnership combines Soufflé’s proprietary ligand and siRNA engineering to deliver therapies directly to cardiomyocytes with Bayer’s cardiovascular development expertise. The program aims to reduce off-target effects and dosing frequency by improving targeted delivery to heart muscle cells. Financial terms and clinical timelines were not disclosed.
Bayer (OTC:BAYRY) will present at the 44th J.P. Morgan Healthcare Conference in San Francisco, held January 12–15, 2026.
Stefan Oelrich, Member of the Board of Management and President of Bayer’s Pharmaceuticals Division, will deliver an update on Bayer’s pharmaceutical growth strategy and pipeline advancements on Tuesday, January 13, 2026, 11:15–11:55 PST. The presentation will be available via live webcast and later posted with related materials on Bayer's website.
Bayer Crop Science (BAYRY) launched Sivanto Energy on December 16, 2025, a foliar insecticide for canola targeting flea beetles.
The product combines two active ingredients — deltamethrin (Group 3) and flupyradifurone (Group 4D) — to offer dual modes of action, rapid knockdown and systemic protection for up to 4 days. Bayer positions the formulation as delivering extended residual control and flexibility for growers managing flea beetle pressure.
Bayer (OTC:BAYRY) announced initiation of the ASSESS Phase IIa randomized, double-blind, placebo-controlled study (NCT07211685) of BAY 3401016, an investigational monoclonal antibody that may block Semaphorin 3A (Sema3A) to address kidney damage in Alport Syndrome (AS).
The first-in-patient adult trial includes an extension phase and follows Bayer’s research collaboration with Evotec. The program has received Fast Track and Orphan Drug designations from the U.S. FDA. The study aims to evaluate the efficacy and safety of BAY 3401016 in slowing loss of kidney function in adults with rapidly progressing AS.
Bayer (OTC:BAYRY) announced that the QUANTI Pediatric study of investigational MRI contrast agent gadoquatrane met primary and secondary endpoints when used at 0.04 mmol Gd/kg—a 60% dose reduction versus macrocyclic GBCAs dosed at 0.1 mmol Gd/kg. The study showed similar pharmacokinetic behavior in children (birth to <18) as in adults. Results were presented at RSNA (Nov 30–Dec 4, 2025).
Based on positive QUANTI data, Bayer has submitted marketing authorization applications for gadoquatrane in multiple markets, including Japan, the U.S., the EU, and China. If approved, gadoquatrane would be the lowest-dose macrocyclic GBCA in those markets.
Bayer (OTC:BAYRY) announced the start of SUNFLOWER, a Phase III investigational study testing the 52 mg levonorgestrel-releasing intrauterine system Mirena for treatment of nonatypical endometrial hyperplasia (NAEH).
The randomized study will compare Mirena versus an oral progestin, plans to enroll 207 patients across about 90 centers in three countries, and is expected to complete after roughly 18 months. Mirena is globally available in more than 120 countries and is approved in the U.S. for contraception (up to 8 years) and for heavy menstrual bleeding (up to 5 years) but is not FDA approved for NAEH. The company cites a high unmet need, noting approximately 121 per 100,000 women develop NAEH each year and current absence of approved U.S. medical therapies.
Bayer Crop Science (OTC:BAYRY) launched EverGol Rise in Canada, a single‑formulation pulse seed treatment combining four active ingredients to expand control to seed‑ and soil‑borne pathogens including ascochyta.
The product is premeasured at 100 ml/100 kg, requires no mixing, offers deeper pigment for visual coverage, and will be sold in 9 L jugs and 27 L drums. Bayer completed over 90 pre‑commercial trials across Western Canada and plans commercial availability for the 2026 growing season.
Bayer (BAYRY) announced on December 1, 2025 that its MEDRAD® Centargo multi-patient CT injection system received FDA 510(k) clearance to expand compatible contrast agent presentations to include single-dose vials in addition to Imaging Bulk Package (IBP) presentations.
The company also added Visipaque (iodixanol) single-dose vials as Centargo’s fifth compatible contrast agent, joining Ultravist (iopromide), Isovue (iopamidol), Optiray (ioversol) and Omnipaque (iohexol). Bayer says the update targets high-throughput imaging suites by enabling greater flexibility, reduced contrast waste, and integration with Bayer’s Cortenic™ Connectivity workflow solutions for scanner and radiology system connectivity.
Bayer (OTC:BAYRY) reported topline Phase III OCEANIC-STROKE results for oral FXIa inhibitor asundexian 50 mg once daily. The study met its primary efficacy and safety endpoints: asundexian plus antiplatelet therapy significantly reduced ischemic stroke risk versus placebo plus antiplatelet therapy, with no increase in ISTH major bleeding. Bayer said it will engage health authorities globally to prepare marketing‑authorization submissions and will present detailed results at an upcoming scientific congress. Asundexian has U.S. FDA Fast Track designation and remains investigational, not approved for any indication.